Skip to main content
custom logo
Enhancing Diabetes Management with the GlycoMark® Test
In support of diabetes awareness, GlycoMark is pleased to offer this complimentary educational program designed for healthcare professionals managing patients with diabetes.
Please join the expert discussion on the latest data and practical clinical experience related to:
• The importance of addressing glycemic variability
• Why A1C alone isn’t enough for assessing glycemic control
• The GlycoMark test: interpretation and clinical utility
• Patient selection for GlycoMark testing

Speakers:
Sam Fereidouni, MD, MHSA
"What’s Next After A1C, the Post-Prandial State"

Gary Scheiner, MS, CDE
"Diabetes Care Beyond (the) Average"

Moderated by:
Jeff Dahlen, PhD
"The GlycoMark Test and its Role in Hyperglycemia Management"
You can choose to attend one or more of the following sessions.

Time shows in Eastern Time (US and Canada)
Loading
* Required information

Speakers

Sam Fereidouni, MD, MHSA
Medical Director @Aveon Health, Scottsdale, AZ
Dr. Fereidouni, a Family Medicine doctor by training, focuses almost exclusively on diabetes. He is the former president of the ADA for Arizona, part of the diabetes coalition for the state and one of the few members of the Am. Assoc. of Clinical Endocrinologists who is not an endocrinologist. He speaks nationally on advances in diabetes care, hypertension, lipid management and related diseases.
Gary Scheiner, MS, CDE
Owner and Clinical Director @Integrated Diabetes Services, LLC, Wynnewood, PA
Gary Scheiner's practice specializes in intensive insulin therapy and advanced education for children and adults. He has been a Certified Diabetes Educator for 22 years and has had Type-1 diabetes for 33 years. He was named 2014 Diabetes Educator of the Year by the AADE. He currently serves on the faculty of Children With Diabetes and the Board of Directors for JDRF.
Jeff Dahlen, PhD
Vice President, Clinical and Scientific Affairs @GlycoMark
Dr. Dahlen has 20 years of experience in clinical, scientific and regulatory affairs. He is responsible for clinical trials, investigator relations, and the clinical and technical application of the GlycoMark Test. He has led numerous clinical trials targeting the diagnosis and management patients with cardiovascular disease, heart failure and diabetes.